ToxIC Fentalog Study Group — Quarterly NPS Report

**PURPOSE:** This report provides new information regarding comprehensive drug testing of clinical toxicology specimens collected after suspected opioid overdoses in cities across the United States (U.S.).

**OVERVIEW:** Drug use can lead to adverse events and overdose scenarios where individuals present to emergency departments (EDs) for clinical evaluation and/or treatment. The culprit can be traditional drugs (e.g., heroin, fentanyl, cocaine, methamphetamine) or novel psychoactive substances (NPS); however, proper drug testing methodologies must be used for accurate identification and characterization. Street-level drug preparations can contain undeclared or unwanted substances (e.g., toxic adulterants or NPS) which can potentiate effects or lead to adverse reactions. Understanding emerging drug trends and drug testing results can help direct new or revised approaches to clinical treatment and harm reduction.

**OBJECTIVE:** A partnership between the American College of Medical Toxicology (ACMT) and the Center for Forensic Science Research and Education (CFSG) was established to comprehensively assess the role and prevalence of synthetic opioids and other drugs among suspected overdose events in the U.S.

**SAMPLE SOURCE:** Patients presented to EDs within ACMT’s Toxicology Investigators Consortium (ToxIC) experiencing a suspected opioid overdose. Residual discarded biological samples were obtained for testing against an expansive library of drugs and other substances. Our findings provide a near real-time assessment of the drug market and allude to resulting implications on clinical institutions.

**TOXICOLOGY TESTING:** Analysis was performed via liquid chromatography quadrupole time-of-flight mass spectrometry (LC-QTOF-MS). The scope of testing targeted more than 1,000 drugs, including a vast majority of NPS and metabolites. Drug classes included opioids, benzodiazepines, cannabinoids, stimulants, and hallucinogens, among other drugs.

**ACKNOWLEDGEMENTS:** This report was prepared by Alex Marin, Alex Krzywilski, Sara Walton, Paul Wex, Jeffrey Brent, Kim Agyi, Rachael Culbreth, Joseph Carpenter, Aleksandar Janjicic, Jennie Buchanan, Bryan Judge, Michael Levine, Diane Caffo, Joshua Shumf, Rob Hendrickson, Adrienne Hughes, and Barry Logan. The authors acknowledge ACMT personnel, ToxIC investigators, and CFSG staff for their contributions. Funding was received from the National Institute on Drug Abuse (NIDA) from the National Institutes of Health (NIH), Award Number: R01DA048009. The opinions, findings, conclusions and/or recommendations expressed in this publication are those of the authors and do not necessarily reflect those of NIDA, NIH, or other agencies. For more information, contact marin@acmt.org or vik@cfsg.org.


---

**NEW CLINICAL SITES!**

**ATLANTA, GA**
- 93% positive for at least one opioid
- Fentanyl (83%) commonly detected, followed by oxycodone (10%) & heroin (7%) 
- Opioid and stimulant use common (54%); opioid and benzodiazepine use (27%)
- Xylazine found alongside fentanyl (12%)
- NPS: Flualprazolam (15%), p-Fluoroentanlyl (12%), Metonitazone (9.7%), Eutylone (9.7%), Borphine (7.3%), Bromazolam (4.9%), N,N-Dimethylpentylone (2.4%)

**DENVER, CO**
- 90% positive for at least one opioid
- Fentanyl (76%) commonly detected, followed by oxycodone (23%) 
- Opioid and stimulant use very common observed (76%); followed by opioid and benzodiazepine use (31%)
- Not: Xylazine not detected
- NPS: N-Cyclohexyl Butylone (8%), p-Fluoroentanlyl (6%), Bromazolam (2%)

**LOS ANGELES, CA**
- 88% positive for at least one opioid
- Fentanyl (80%) commonly detected
- Opioid and stimulant use commonly observed (70%); while opioid and benzodiazepine use less common (25%)
- Not: Xylazine not detected
- NPS: p-Fluoroentanlyl (15%), Bromazolam (5%), Flualprazolam (2.5%), Clonazolam (2.5%), N,N-Dimethylpentylone (2.5%), Metonitazone (2.5%)

**PORTLAND, OR**
- 100% positive for at least one opioid
- Fentanyl (56%) commonly detected, followed by heroin (22%)
- Opioid and stimulant use commonly detected (67%); opioid and benzodiazepine use also common (44%)
- Not: Xylazine and Fluoroentanlyl not detected
- NPS: Clonazolam (11%)

**PITTSBURGH, PA**
- 90% positive for at least one opioid
- Fentanyl (88%) most commonly detected, followed by methadone (13%)
- Opioid and stimulant (33%) and opioid and benzodiazepine (23%) use observed
- Xylazine found alongside fentanyl (45%)
- NPS: Bromazolam (10%), p-Fluoroentanlyl (8%), Clonazolam (5%), Etizolam (2.5%), N-Desethyl Isotonitazone (2.5%)

---

**NEW YORK, NY**
- 82% positive for at least one opioid
- Fentanyl (73%) most commonly detected, followed by methadone (14%)
- Opioid and stimulant use (37%); and opioid and benzodiazepine (27%) use observed
- Xylazine found alongside fentanyl (26%)
- NPS: p-Fluoroentanlyl (8%), Bromazolam (8.2%), Flubromazepam (6.8%), Clonazolam (2.7%), Etizolam (1.4%)

---

**BETHLEHEM, PA**
- 75% positive for at least one opioid
- Fentanyl (63%) only traditional opioid
- Opioid and stimulant (25%) and opioid and benzodiazepine (25%) use observed
- Xylazine found alongside fentanyl (25%)
- NPS: Bromazolam (25%), N-Cyclohexyl Butylone (25%), p-Fluoroentanlyl (13%), Flubromazepam (13%)

---